Insider Trading Activity Aduro BioTech Inc (NASDAQ:ADRO) – CEO Sold 40,000 shares of Stock

Insider Trading Activity For Aduro BioTech Inc (NASDAQ:ADRO)

Story continues below

Stephen T Isaacs , CEO of Aduro BioTech Inc (NASDAQ:ADRO) reportedly Sold 40,000 shares of the company’s stock at an average price of 12.19 for a total transaction amount of $487,600.00 SEC Form

Insider Trading History For Aduro BioTech Inc (NASDAQ:ADRO)

  • On 4/20/2015 William Mariner Greenman, Director, bought 3,000 with an average share price of $17.00 per share and the total transaction amounting to $51,000.00.View SEC Filing
  • On 4/20/2015 Venture (Vi) Inves Morningside, Major Shareholder, bought 441,176 with an average share price of $17.00 per share and the total transaction amounting to $7,499,992.00.View SEC Filing
  • On 4/20/2015 Jennifer Lew, VP, bought 2,000 with an average share price of $17.00 per share and the total transaction amounting to $34,000.00.View SEC Filing
  • On 11/16/2015 Stephen T. Isaacs, CEO, sold 25,000 with an average share price of $27.54 per share and the total transaction amounting to $688,500.00.View SEC Filing
  • On 11/17/2015 Thomas W. Dubensky, insider, sold 31,470 with an average share price of $28.27 per share and the total transaction amounting to $889,656.90.View SEC Filing
  • On 11/17/2015 Gregory W. Schafer, COO, sold 26,470 with an average share price of $28.15 per share and the total transaction amounting to $745,130.50.View SEC Filing
  • On 11/18/2015 Jennifer Lew, VP, sold 6,712 with an average share price of $28.52 per share and the total transaction amounting to $191,426.24.View SEC Filing
  • Analyst Ratings For Aduro BioTech Inc (NASDAQ:ADRO)
    These are 7 Buy Ratings .
    The current consensus rating for Aduro BioTech Inc (NASDAQ:ADRO) is Buy (Score: 3.00) with a consensus target price of $20.00 , a potential (64.61% upside)

    Analyst Ratings History For Aduro BioTech Inc (NASDAQ:ADRO)

    • On 12/1/2015 Oppenheimer Holdings, Inc. Downgraded rating Outperform to Market Perform
    • On 2/2/2016 William Blair Initiated Coverage of rating Buy
    • On 3/15/2016 Bank of America Corporation Downgraded rating Buy to Underperform with a price target of $32.00 to $14.00
    • On 10/24/2016 Leerink Swann Set Price Target of rating Buy with a price target of $14.00
    • On 3/7/2017 Roth Capital Reiterated Rating Buy with a price target of $17.00
    • On 3/7/2017 FBR & Co Reiterated Rating Buy with a price target of $23.00
    • On 5/1/2017 Rodman & Renshaw Initiated Coverage of rating Buy to Buy with a price target of $18.00

    Recent Trading Activity for Aduro BioTech Inc (NASDAQ:ADRO)
    Shares of Aduro BioTech Inc closed the previous trading session at 12.15 down -0.15 -1.22% with 354,202 shares trading hands.

    An ad to help with our costs